INTENSITY THERAPEUTICS, INC. 8K

Intensity Therapeutics reported Q2 2026 results, restarted key INVINCIBLE-3 and INVINCIBLE-4 clinical trial activities under amended protocols, disclosed encouraging preliminary TNBC data, and detailed recent ATM equity financings and its $9.5 million cash position.

On August 11, 2026, Intensity Therapeutics, Inc. reported its second quarter 2026 financial results and provided a business update, highlighting the restart of activities to resume enrollment at selected U.S. sites in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study under an FDA‑reviewed amended protocol, the July 2026 restart of patient treatment in its Phase 2 INVINCIBLE-4 presurgical triple negative breast cancer trial following dosing revisions and EU protocol approvals, preliminary INVINCIBLE-4 data showing higher pathological complete response rates and fewer grade 3 adverse events when INT230-6 is added to standard of care, the establishment of a $60 million at-the-market equity facility and raising of $2.9 million in net proceeds through June 30 and subsequent to quarter end, and financials that included a $3.0 million quarterly net loss and $9.5 million in cash and cash equivalents as of June 30, 2026.

Filing Facts

CIK

1567264

Ticker

-

Form

8K

Source Type

sec

Accession

0001567264-26-000061

Alert Tier

6